Acurx Pharmaceuticals Reports 51% Reduction in Financial Losses for Q1 2025

Acurx Pharmaceuticals, Inc. reported a significant reduction in its financial losses for the first quarter of 2025, with a net loss of $2.1 million compared to $4.4 million in the same period of 2024, marking a 51% decrease. The company’s total operating expenses also fell by 51% to $2.1 million, down from $4.4 million a year earlier. This decline was primarily driven by a 61% reduction in research and development expenses, which totaled $598,798, and a 45% decrease in general and administrative expenses, which amounted to $1.6 million. The decrease in expenses reflects the company's strategic focus on cost management as it continues to develop its antibiotic candidates.

In terms of capital, Acurx raised approximately $3 million through registered direct offerings in January and March 2025, contributing to a cash balance of $4.6 million as of March 31, 2025. However, the company noted that this amount may not be sufficient to meet its anticipated cash requirements for at least the next 12 months. Acurx has indicated plans to seek additional equity financing to support its operations, which raises concerns about its ability to continue as a going concern, as highlighted by its independent auditors.

Operationally, Acurx is focused on advancing its lead product candidate, ibezapolstat, which targets Clostridioides difficile infections. The company is in the late stages of clinical development and is exploring partnerships for late-stage clinical trials and commercialization. Acurx has not generated any revenue since its inception and continues to rely on external funding to support its research and development activities. The company is also evaluating strategic transactions, including potential collaborations or licensing agreements, to enhance its financial position and operational capabilities.

Acurx's stock performance has been under scrutiny, particularly following notifications from Nasdaq regarding non-compliance with minimum stockholders' equity and bid price requirements. The company has submitted a compliance plan to address these issues, but there is no guarantee that it will regain compliance. The potential for delisting from Nasdaq could adversely affect the company's marketability and investor confidence. As Acurx navigates these challenges, it remains committed to its mission of developing innovative antibiotics to combat serious bacterial infections, while also managing its financial and operational risks.